Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

NCT04555486 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperoxaluria Type 3

Interventions

DRUG: DCR-PHXC
DRUG: Sterile Normal Saline (0.9% NaCl)

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company